Enanta shares rise despite RSV trial failing to meet main goal

Core Insights - Enanta Pharmaceuticals' shares increased despite the company not meeting the primary objective in a mid-stage trial for its antiviral drug, zelicapavir, which targets respiratory syncytial virus infections [3]. Company Summary - Enanta Pharmaceuticals reported that it did not achieve the primary objective in its mid-stage trial for zelicapavir [3]. - The stock price of Enanta Pharmaceuticals rose on the day of the announcement [4].